Introduction
Onychomycosis is a common nail disorder thought to occur in approximately 7-9% of the North American population.v" Until quite recently, there was a paucity of effective and safe therapies for onychomycosis, particularly pedal disease. Griseofulvin was the first significant oral antifungal agent to become available for the treatment of onychomycosis.v? Since then, other oral antifungal agents have been reported for use in this disorder: . ketoconazole, itraconazole, terbinafine, and fluconazole.
In this article, the literature pertaining to fluconazole therapy for the management of onychomycosis is reviewed. The advantages of fluconazole include its high efficacy rate, low relapse rate, broad action spectrum, weekly treatment regimen that results in high compliance, and a favorable adverse effects profile. Fluconazole was first approved in France and the UK in 1988 for systemic mycoses. It is estimated that fluconazole has now been used more than 50 million times worldwide (Pfizer, USA, personal communication, May 1997).
Pharmacokinetics
The pharmacokinetics of once weekly fluconazole suggest that it should be effective in the management of onychomycosis. It rapidly enters the nail plate once treatment is initiated. H ay8 measured fluconazole in the nail plate within I day of starting the drug, 50 mg once weekly, for 14 consecutive days. On days I and 14 after starting therapy, the concentrations of fluconazole in the nail plate were 1. 3I ug/g and 1.80 ug/g, respectively. 8 
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The corresponding levels in the plasma were 0.7 6 Ilg! mL and 2. I 2 ug/ml., respectively. The fluconazole concentration in the nail plate increases with the length of therapy, with the drug concentration being comparable in both plate and plasma at the end of treatment. 8 Faergemann and Laufen? measured fluconazole concentrations in fungal toenails of 36 patients treated using a regimen of 150 mg once weekly for 12 months, or stopping therapy earlier if cured. During treatment, there was no statistically significant difference between healthy and diseased nails." however, the concentration of fluconazole in nails was significantly higher than that in serum. After I and 6 months of therapy, the mean concentrations of fluconazole in healthy nails were 3.09 Ilg!g and 8.54 ug/g, respectively.? In contrast, the serum concentration of fluconazole remained more or less stable at 0.45-1.36 ug/rnl, during therapy. Six months following discontinuation of the drug, fluconazole concentrations in healthy and diseased toenails were 1.4 Ilg!g and 1.9 ug/g, respectively (n = 3 patients}?
The data suggest that there is the potential for ongoing improvement in onychomycosis even after discontinuation of active drug therapy.
The pharmacokinetics of fluconazole in onychomycosis have also been studied in a dose-finding, placebocontrolled study where fluconazole (150 mg, 300 mg, 450 mg) or matching placebo was administered once weekly for the treatment of onychomycosis of the toes. The above is only a guideline of the main interactions. In some cases, studies may not have been conducted with other medications, but such interactions may occur. Consult up-to-date product monograph and other authoritative texts before prescribing.
the three groups treated with active drug, Rich et at. 10 reported that 8 months after starting therapy, the ratio of fluconazole in the nails to plasma ranged from 1.3 I to 1. 5. These results, where higher concentrations of fluconazole are present in the nail compared with plasma, are similar to the data reported by Faergemann and Laufen.? Rich"? also found that, after fluconazole therapy was stopped, the concentrations of the active drug in toenails decreased gradually with elimination half-lives in the. 150 mg, 300 mg, and 450 mg groups of 2.5, 2·4, and 3.7 months, respectively. In fact, in most subjects, fluconazole could still be detected in the nail plate 6 months after therapy was discontinued. Fluconazole has several other pharmacokinetic properties that are of benefit to patients being treated for onychomycosis. I I Its bioavailability when taken orally is at least 90%. It is important to note that the absorption of orally administered fluconazole is not reduced in the presence of antacids,I2,I3 by the concurrent intake of a histarnine-z receptor (Hj-receptor] antagonist.Hi"! or in patients who experience frequent vomiting.I" Fluconazole has a relatively low lipophilicity and distributes widely to body tissues and fluids."? In healthy volunteers, it shows approximately 12% plasma protein binding.V Unlike the other azoles ketoconazole and itraconazole, fluconazole is eliminated predominantly by the renal rather than hepatic route.':' Its half-life of approximately 30 h is longer than those of ketoconazole and itracona-
Efficacy
Fluconazole has been shown to be effective and safe for the treatment of onychomycosis in case reports, open and double-blind studies (Table I) . A placebo-controlled, randomized, double-blind, dosefinding trial has recently been completed where once weekly doses of fluconazole (150 mg, 300 mg, 450 mg) were prescribed to treat distal and lateral subungual onychomycosis of the toeY Scher P randomized 362 patients with mycologically confirmed dermatophyte onychomycosis to receive fluconazole, 150 mg, 300 mg, or 450 mg once weekly, for a maximum of 12 months. To be included in the study the target toenail had to be at least 25% involved and have at least 2 mm of healthy nail along the proximal nail foldY For those patients who were cured, the average time to cure was 6-7 months, with significant clinical improvement being noted as early as 3 months after starting therapy. At the end of treatment, clinical success (defined as cure or improvement sufficient to reduce the involved target area of the nail to < 25%) occurred in 86% (150 mg group, n = 79), 87% (300 mg group, n = 75), and 89% (450 mg group, n = 80) patients, respectivelyY Clinical
International Journal of Dermatology 1998, 37, 815-820 success was recorded in only 8% of the placebo group. At the 6-month post-treatment assessment, clinical success in the 150 mg, 300 mg, and 450 mg groups was 77%, 79%, and 86%, respectively. The corresponding value for the placebo group was 3%. There was no statistical significance between the three fluconazole dosage groups in the rate of clinical success.P At this time point, the clinical relapse in the 150 mg, 300 mg, 450 mg, and placebo groups was 0%, 5%, 7%, and 0%, respectively.P In addition, the end-of-treatment mycologic responses in the 150 mg (n = 79), 300 mg (n = 75), 450 mg (n = 79) and placebo (n = 78) groups were 47%, 59%, 62 %, and 14%, respectively.P The time to mycologic cure was 10.1 months in the 150 mg group, 8.8 months in the 300 mg group, and 9.6 months in the 450 mg group.s ' At follow-up, 6 months after the completion of active therapy, the mycologic cure rates in the 150 mg, 300 mg, 450 mg, and placebo groups were 53%, 59%, 61%, and 16%, respectively. Other studies suggest that fluconazole may also be effective in onychomycosis associated with Candida species 29 ,F ,34 and nondermatophyte molds.t ' and in chronic mucocutaneous candidiasis.tt
Adverse effects
The data on the adverse effects profile of fluconazole when used for the treatment of onychomycosis can be derived from single case reports, open and double-blind trials. 8,24-3 2 In considering the first two categories, there are several reports on the treatment of onychomycosis, with a total of 143 patients on whom adverse effects data are available. While not all the protocols are identical, they are similar enough to allow the grouping together of adverse effects data so that a better idea of the safety profile of fluconazole when used to treat onychomycosis can be obtained. In nine published reports,8,24-3 I adverse effects were observed in seven (4.9%) of 143 patients. These included nausea, headaches (two patients, one discontinued treatment), insomnia, palpitations (patient discontinued therapy), pruritus, sweating, fever, and elevation of liver function tests (LITs) (in one patient who discontinued therapy and LFTs returned to normal). In these reports, three (2.1%) of 143 patients discontinued therapy.8,2 4-F . Smith et aty noted that the majority of the adverse events in their patients receiving fluconazole occurred within the first month.
It is always preferable to compare the adverse effects associated with any drug with placebo. In a recent dosefinding study where once weekly fluconazole (150 mg, 300 mg, 450 mg) or placebo was given for onychomycosis, the adverse events were generally mild to moderate III International Journal of Dermatology 1998, 37, 815-820 Gupta, Scher, and Rich severity, the most common being, for the fluconazole vs. placebo groups, headache (6% vs. 2%), abdominal pain (4% vs. 3%), respiratory disorders (4% vs. 3%), diarrhea (3% vs. 2%)', eruption (3% vs. 2%), and nausea (2% vs. 3%).32 Fluconazole was discontinued due to a laboratory abnormality in the following proportions of patients: 150 mg group (1%, AR to fluconazole: 0%), 300 mg group (2%, AR: 1%), 450 mg group (1%, AR: 0%), and placebo (1%))2 The changes in the median laboratory values in the fluconazole and placebo groups were similar; none of the changes in the laboratory parameters in the active drug group were clinically significant. Five patients (four in the fluconazole group and one in the placebo group) discontinued the study due to LFT abnormalities. The changes in the LFTs were considered to be drug-related in the following instances: 150 mg group (one patient), 300 mg group (one patient), and placebo group (one patient).
Drug interactions (Table 2) 5-38
The clinical significance of fluconazole tablets coadministered with ethinyl estradiol-and levonorgestrel-containing oral contraceptives is presently unknown. In some patients, there were decreases of up to 47% and 33 % in ethinyl estradiol and levonorgestrellevels. The decreases in some individual ethinyl estradiol and levonorgestrel area under the curve (AUq values with fluconazole treatment are probably the result of random variation. While fluconazole may inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that it is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
Coadministration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg or higher. Also, coadministration with cisparide is contraindicated.
Fluconazole may interact with sulfonylurea hypoglycemic agents (e.g. tolbutamide, glipizide, and glyburide) and produce hypoglycemia. In some instances, the drug interaction may occur through the cytochrome P450 2C9 subfamily.
Conclusions
Fluconazole administered once weekly has been found to be effective in onychomycosis. The drug is detectable in toenails for 6 months or even longer following the discontinuation of therapy (150 mg or 300 mg administered once weekly until complete clinical and mycologic cure was obtained, or for a maximum period of 12 months). The relapse rate of onychomycosis is low. The preferred once weekly dosage may be 150 mg or 300 mg for the treatment of pedal onychomycosis. Fluconazole has a favorable adverse effects profile with a high compliance to the treatment regimen. The drug is an important addition to the armamentarium of oral agents available to treat onychomycosis.
